Oculis Board Member Lionel Carnot Resigns After Nine Years
Event summary
- Lionel Carnot, a director at Oculis Holding AG, resigned from the board effective September 30, 2026, after nearly a decade of service.
- Carnot's departure is not due to any disagreement with the company but rather a personal decision to focus on other commitments.
- The board will now consist of eight members, with Geraldine O’Keeffe taking over as chair of the Remuneration Committee.
- Oculis will begin identifying a successor for Carnot, with the vacancy to be filled at a future annual or special general meeting.
The big picture
Lionel Carnot's resignation marks the end of an era for Oculis, as the company transitions from a startup to a publicly listed late-stage biopharmaceutical firm. His departure highlights the evolving governance needs of a growing company in the competitive neuro-ophthalmology space. The move comes at a critical juncture as Oculis advances its pipeline, including Privosegtor and Licaminlimab, which are key to its strategic positioning.
What we're watching
- Governance Dynamics
- How the transition in the Remuneration Committee leadership will impact board operations and strategic decisions.
- Succession Planning
- The pace at which Oculis identifies and appoints a successor for Lionel Carnot, and the profile of the candidate.
- Investor Confidence
- Whether Carnot's continued support as an investor will mitigate any potential market concerns over his departure.